129 related articles for article (PubMed ID: 15231575)
1. Evaluation of different methods of leukoreduction of donor platelets to prevent alloimmune platelet refractoriness and induce tolerance in a canine transfusion model.
Slichter SJ; Fish D; Abrams VK; Gaur L; Nelson K; Bolgiano D
Blood; 2005 Jan; 105(2):847-54. PubMed ID: 15231575
[TBL] [Abstract][Full Text] [Related]
2. Leukofiltration plus pathogen reduction prevents alloimmune platelet refractoriness in a dog transfusion model.
Slichter SJ; Pellham E; Bailey SL; Christoffel T; Gettinger I; Gaur L; Latchman Y; Nelson K; Bolgiano D
Blood; 2017 Aug; 130(8):1052-1061. PubMed ID: 28705838
[TBL] [Abstract][Full Text] [Related]
3. Further studies to evaluate methods of leucoreduction to prevent alloimmune platelet refractoriness and induce tolerance in a dog platelet transfusion model.
Slichter SJ; Abrams K; Bailey SL; Pellham E; Gettinger I; Christoffel T; Gaur L; Latchman Y; Nelson K; Bolgiano D
Vox Sang; 2016 Jul; 111(1):62-70. PubMed ID: 27007858
[TBL] [Abstract][Full Text] [Related]
4. Ultraviolet B irradiation in the prevention of alloimmunization in a dog platelet transfusion model.
Slichter SJ; Abrams K; Gettinger I; Christoffel T; Gaur L; Latchman Y; Nelson K; Pellham E; Bailey SL; Bolgiano D
Transfusion; 2016 Jun; 56(6):1340-7. PubMed ID: 27184061
[TBL] [Abstract][Full Text] [Related]
5. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions.
Trial to Reduce Alloimmunization to Platelets Study Group
N Engl J Med; 1997 Dec; 337(26):1861-9. PubMed ID: 9417523
[TBL] [Abstract][Full Text] [Related]
6. Pathogen reduction with amotosalen/UVA reduces platelet refractoriness in a dog platelet transfusion model.
Slichter SJ; Bailey SL; Gettinger I; Pellham E; Christoffel T; Castro G; Green JM; Stassinopoulos A
Vox Sang; 2019 Aug; 114(6):595-604. PubMed ID: 31297836
[TBL] [Abstract][Full Text] [Related]
7. Transfusion-related immunomodulation: gamma irradiation alters the effects of leukoreduction on alloimmunization.
Nelson KA; Aldea GS; Warner P; Latchman Y; Gunasekera D; Tamir A; Gernsheimer T; Bolgiano D; Slichter SJ
Transfusion; 2019 Nov; 59(11):3396-3404. PubMed ID: 31608454
[TBL] [Abstract][Full Text] [Related]
8. Determination
Thuku NW; Shikuku K; Mbugua A
Pan Afr Med J; 2017; 27():226. PubMed ID: 28979628
[TBL] [Abstract][Full Text] [Related]
9. Canine platelet alloimmunization: the role of donor selection.
Slichter SJ; O'Donnell MR; Weiden PL; Storb R; Schroeder ML
Br J Haematol; 1986 Aug; 63(4):713-27. PubMed ID: 3730294
[TBL] [Abstract][Full Text] [Related]
10. Alloimmune refractoriness to platelet transfusions.
Sandler SG
Curr Opin Hematol; 1997 Nov; 4(6):470-3. PubMed ID: 9359008
[TBL] [Abstract][Full Text] [Related]
11. The challenge of platelet alloimmunization: management and prevention.
Kickler TS
Transfus Med Rev; 1990 Oct; 4(4 Suppl 1):8-18. PubMed ID: 2134640
[TBL] [Abstract][Full Text] [Related]
12. Prevention of platelet alloimmunization in dogs with systemic cyclosporine and by UV-irradiation or cyclosporine-loading of donor platelets.
Slichter SJ; Deeg HJ; Kennedy MS
Blood; 1987 Feb; 69(2):414-8. PubMed ID: 3801661
[TBL] [Abstract][Full Text] [Related]
13. Reduced alloimmunization in mice following repeated transfusion with pathogen-reduced platelets.
Muench MO; Heitman JW; Inglis H; Fomin ME; Marschner S; Goodrich RP; Norris PJ; Jackman RP
Transfusion; 2016 Jun; 56(6):1419-29. PubMed ID: 27028210
[TBL] [Abstract][Full Text] [Related]
14. Analysis of platelet-reactive alloantibodies and evaluation of cross-match-compatible platelets for the management of patients with transfusion refractoriness.
Wang J; Xia W; Deng J; Xu X; Shao Y; Ding H; Chen Y; Liu J; Chen D; Ye X; Santoso S
Transfus Med; 2018 Feb; 28(1):40-46. PubMed ID: 28516675
[TBL] [Abstract][Full Text] [Related]
15. Storage-Induced Platelet Apoptosis Is a Potential Risk Factor for Alloimmunization Upon Platelet Transfusion.
Saris A; Peyron I; van der Meer PF; Stuge TB; Zwaginga JJ; van Ham SM; Ten Brinke A
Front Immunol; 2018; 9():1251. PubMed ID: 29951051
[TBL] [Abstract][Full Text] [Related]
16. An animal model of allogeneic donor platelet refractoriness: the effect of the time of leukodepletion.
Blajchman MA; Bardossy L; Carmen RA; Goldman M; Heddle NM; Singal DP
Blood; 1992 Mar; 79(5):1371-5. PubMed ID: 1536960
[TBL] [Abstract][Full Text] [Related]
17. Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness.
Seftel MD; Growe GH; Petraszko T; Benny WB; Le A; Lee CY; Spinelli JJ; Sutherland HJ; Tsang P; Hogge DE
Blood; 2004 Jan; 103(1):333-9. PubMed ID: 12958065
[TBL] [Abstract][Full Text] [Related]
18. [Platelet allo-antibodies identification strategies for preventing and managing platelet refractoriness].
Basire A; Picard C
Transfus Clin Biol; 2014 Nov; 21(4-5):193-206. PubMed ID: 25277423
[TBL] [Abstract][Full Text] [Related]
19. Immune Unresponsiveness to platelets. A case study.
Pegels JG; Bruynes EC; Korthals Altes HR; Engelfriet CP; von dem Borne AE
Vox Sang; 1982; 42(4):211-6. PubMed ID: 7046248
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis and treatment of immunological platelet refractoriness by histocompatibility.
Fagundes IS; Franz JM; Jobim MS; Arend A; Merzoni J; Cardone JM; Gil B; Sekine L; Jobim LF
Hum Immunol; 2020 May; 81(5):197-201. PubMed ID: 32067841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
